We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

115 hedge funds and large institutions have $867M invested in Coherus Oncology in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 25

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

58% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $9.23M

42% more capital invested

Capital invested by funds: $611M → $867M (+$256M)

12% more funds holding

Funds holding: 103 → 115 (+12)

2.9% more ownership

Funds ownership: 91.94% → 94.83% (+2.9%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
115
Holders Change
+12
Holders Change %
+11.65%
% of All Funds
2.63%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
48
Reduced
25
Closed
15
Calls
$14.6M
Puts
$9.23M
Net Calls
+$5.39M
Net Calls Change
+$4.38M

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$12.1M
2
BlackRock
BlackRock
New York
+$11.6M
3
HP
Hound Partners
New York
+$11.1M
4
Deutsche Bank
Deutsche Bank
Germany
+$9.04M
5
MWNA
Marshall Wace North America
New York
+$8.95M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.47M
2
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$4.15M
3
HCM
Highbridge Capital Management
New York
-$4.14M
4
SFM
Sphera Funds Management
Israel
-$2.98M
5
Ameriprise
Ameriprise
Minnesota
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$5.72M +$74.5K +5,203 +1%
Alyeska Investment Group
27
Alyeska Investment Group
Illinois
$5.58M -$828K -57,860 -13%
RPAM
28
Rhenman & Partners Asset Management
Sweden
$4.9M – – –
ACP
29
Acuta Capital Partners
California
$4.83M +$4.94M +345,000 New
RCMNY
30
Rubric Capital Management (New York)
New York
$4.78M -$1.74M -121,906 -26%
Mirae Asset Global Investments
31
Mirae Asset Global Investments
South Korea
$4.61M +$4.71M +329,144 New
Balyasny Asset Management
32
Balyasny Asset Management
Illinois
$4.49M +$4.37M +305,572 +2,072%
Point72 Asset Management
33
Point72 Asset Management
Connecticut
$4.38M +$4.48M +312,800 New
Morgan Stanley
34
Morgan Stanley
New York
$4.12M +$1.42M +99,324 +51%
CWG
35
C WorldWide Group
Denmark
$3.74M +$1.34M +93,942 +54%
HCMT
36
Highland Capital Management (Texas)
Texas
$3.68M -$1.19M -82,973 -24%
Goldman Sachs
37
Goldman Sachs
New York
$3.61M -$2.23M -155,979 -38%
Charles Schwab
38
Charles Schwab
California
$3.59M +$646K +45,144 +21%
PC
39
Pier Capital
Connecticut
$3.53M +$3.61M +252,243 New
Wells Fargo
40
Wells Fargo
California
$3.44M +$391K +27,307 +13%
TCM
41
Tekla Capital Management
Massachusetts
$3.37M +$856K +59,820 +33%
USAA
42
United Services Automobile Association
Texas
$3.31M -$33.7K -2,357 -1%
Ameriprise
43
Ameriprise
Minnesota
$3.1M -$2.74M -191,105 -46%
CS
44
Credit Suisse
Switzerland
$3.07M +$1.03M +71,691 +49%
BG
45
Bellevue Group
Switzerland
$2.77M +$685K +47,835 +32%
TRSOTSOK
46
Teachers Retirement System of the State of Kentucky
Kentucky
$2.77M – – –
Bank of New York Mellon
47
Bank of New York Mellon
New York
$2.61M +$133K +9,299 +5%
Two Sigma Investments
48
Two Sigma Investments
New York
$2.45M +$2.51M +175,072 New
Citigroup
49
Citigroup
New York
$2.35M +$488K +34,091 +26%
PIM
50
Platinum Investment Management
Australia
$1.92M – – –
1
2
3 4 5

CHRS Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2018, worth a combined $867M — up 42% from $611M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CHRS positions and 15 closed out — a net gain of 12 holders — while 48 added to existing stakes and 25 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $12.1M. The largest seller was Fidelity Investments, cutting an estimated $8.47M.

  • 115 institutional investors held Coherus Oncology (CHRS) as of Q2 2018, up from 103 in Q1 2018.
  • Funds reported $867M of Coherus Oncology stock for Q2 2018, up 42% quarter-over-quarter.
  • 27 funds opened new Coherus Oncology positions in Q2 2018 and 15 closed out, a net change of +12 holders.
  • The largest Coherus Oncology buyer in Q2 2018 was Farallon Capital Management, an estimated $12.1M added.
  • The largest Coherus Oncology seller in Q2 2018 was Fidelity Investments, an estimated $8.47M sold.

Based on aggregated 13F filings for Q2 2018.